Compare AbbVie Inc (ABBV) vs Avantis US Small Cap Value ETF (AVUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Avantis US Small Cap Value ETF — how do they compare? AbbVie Inc trades at $248.68 (market cap $438.19B), while Avantis US Small Cap Value ETF trades at $127.31. The key difference: AbbVie Inc pays a 2.79% dividend while Avantis US Small Cap Value ETF pays none, and Avantis US Small Cap Value ETF is trading nearer its 52-week high, AbbVie Inc nearer its low. Which is the better fit depends on your goals.
| ABBV | AVUV | |
|---|---|---|
Market Cap | $438.19B | — |
Sector | Health | Sector/Thematic |
52-Week High | $263.58 | $128.74 |
52-Week Low | $197.38 | $93.93 |
Enterprise Value | $502.45B | — |
Dividend Yield | 2.79% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABBV trades at $247.91, up 0.76% today, with a bullish technical signal supported by moving averages and oversold RSI levels. The company reported Q2 2026 EPS of $3.65, beating expectations, and maintains strong profitability with a 71.48% gross margin. Recent news highlights positive Phase 2 data for ELAHERE in ovarian cancer, reinforcing growth prospects beyond Humira's patent expiry.
Outlook is positive with analyst consensus target of $278.69, though high P/E of 70.05 and debt levels pose valuation and financial risks. Revenue growth driven by Skyrizi and Rinvoq offsets competitive pressures, but patent cliffs in the 2030s require monitoring. The stock offers dividend appeal with a $1.73 payout scheduled for August 2026.
AVUV trades at $126.88, up 0.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights strong small-cap value performance and potential benefits from rate outlook shifts. The ETF focuses on U.S. small-cap value stocks, offering diversification from tech-heavy portfolios.
Outlook remains positive due to small-cap momentum and value factor tailwinds, but risks include higher volatility and sensitivity to interest rates. Analyst sentiment is favorable, emphasizing long-term growth potential in tax-advantaged accounts like Roth IRAs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Avantis US Small Cap Value ETF
AVUV is an actively managed ETF that targets small-cap value companies in the United States. It uses a systematic, rules-based process to identify firms with low valuations and high profitability, aiming to capture the historical premiums of 'size' and 'value' while filtering for financial quality.
Read more on AVUV →
